Stoke Therapeutics (NASDAQ:STOK) Sets New 12-Month High - Still a Buy?

Key Points

• Stoke Therapeutics' stock reached a new 52-week high of $27.56, reflecting significant trading volume and interest.
• Analysts have a consensus "Buy" rating on the stock, with price targets ranging from $22 to $30, noting strong potential for growth.
• Insider trading activity has seen notable sales, with executives reducing their positions in the company, which may indicate a mixed outlook among insiders.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $27.50 and last traded at $27.56, with a volume of 72488 shares traded. The stock had previously closed at $25.56.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Wedbush boosted their price target on Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a research note on Wednesday, August 13th. Needham & Company LLC restated a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, July 1st. Weiss Ratings reiterated a "sell (d+)" rating on shares of Stoke Therapeutics in a research report on Saturday, September 27th. Jefferies Financial Group began coverage on shares of Stoke Therapeutics in a research note on Friday, July 18th. They set a "buy" rating and a $30.00 price target on the stock. Finally, BTIG Research set a $28.00 price objective on Stoke Therapeutics and gave the stock a "buy" rating in a research note on Monday, August 18th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Stoke Therapeutics has an average rating of "Buy" and a consensus target price of $25.57.

Stoke Therapeutics Stock Performance

The company has a market cap of $1.48 billion, a P/E ratio of 31.90 and a beta of 1.24. The business's fifty day moving average is $19.36 and its two-hundred day moving average is $13.18.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%.The business had revenue of $13.82 million during the quarter, compared to analysts' expectations of $31.51 million. Analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 5,501 shares of Stoke Therapeutics stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total transaction of $109,304.87. Following the completion of the sale, the insider owned 18,469 shares of the company's stock, valued at approximately $366,979.03. The trade was a 22.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Edward M. Md Kaye sold 45,996 shares of the company's stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $20.13, for a total value of $925,899.48. Following the completion of the sale, the director owned 91,585 shares in the company, valued at $1,843,606.05. The trade was a 33.43% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 107,719 shares of company stock valued at $2,063,359. Insiders own 9.50% of the company's stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Corient Private Wealth LLC purchased a new position in Stoke Therapeutics during the second quarter valued at $7,489,000. Osaic Holdings Inc. lifted its stake in Stoke Therapeutics by 263.3% in the 2nd quarter. Osaic Holdings Inc. now owns 7,488 shares of the company's stock valued at $85,000 after buying an additional 5,427 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock worth $50,000 after buying an additional 3,591 shares during the last quarter. Opaleye Management Inc. boosted its stake in shares of Stoke Therapeutics by 87.4% in the second quarter. Opaleye Management Inc. now owns 562,120 shares of the company's stock worth $6,380,000 after acquiring an additional 262,120 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new position in Stoke Therapeutics in the 2nd quarter valued at $156,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.